Article Text

PDF

Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention
  1. Ashley A Hibberd1,
  2. Anna Lyra2,
  3. Arthur C Ouwehand2,
  4. Peter Rolny3,
  5. Helena Lindegren3,
  6. Lennart Cedgård,
  7. Yvonne Wettergren4,5
  1. 1Department of Genomics and Microbiome Science, DuPont Nutrition & Health, Saint Louis, Missouri, USA
  2. 2Department of Kantvik Active Nutrition, DuPont Global Health & Nutrition Science, Kantvik, Finland
  3. 3Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  4. 4Probiotic Division, Wasa Medicals AB, Halmstad, Sweden
  5. 5Department of Surgery, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  1. Correspondence to Dr Yvonne Wettergren; yvonne.wettergren{at}dep-surg.gu.se

Abstract

Objective The colonic microbiota is altered in patients with colorectal cancer (CRC). We investigated the microbiota composition of patients with colon cancer compared with controls devoid of neoplastic or inflammatory disease and the potential to modify the colonic microbiota with probiotics.

Design Biopsy samples were obtained from the normal mucosa and tumour during colonoscopy from 15 patients with colon cancer. Subsequent patient-matched samples were taken at surgery from the tumour and nearby mucosa from the patients with cancer, eight of whom had received two daily tablets totalling 1.4×1010 CFUs Bifidobacterium lactis Bl-04 and 7×109 CFUs Lactobacillus acidophilus NCFM. Faecal samples were obtained after colonoscopy prior to starting the intervention and at surgery. In addition, 21 mucosal biopsies from non-cancer controls were obtained during colonoscopy followed by later faecal samples. The colonic and faecal microbiota was assessed by 16S rRNA gene amplicon sequencing.

Results The tumour microbiota was characterised by increased microbial diversity and enrichment of several taxa including Fusobacterium, Selenomonas and Peptostreptococcus compared with the control microbiota. Patients with colon cancer that received probiotics had an increased abundance of butyrate-producing bacteria, especially Faecalibacterium and Clostridiales spp in the tumour, non-tumour mucosa and faecal microbiota. CRC-associated genera such as Fusobacterium and Peptostreptococcus tended to be reduced in the faecal microbiota of patients that received probiotics.

Conclusions Patients with colon cancer harbour a distinct microbiota signature in the tumour tissue and nearby mucosa, which was altered with probiotic intervention. Our results show promise for potential therapeutic benefits in CRC by manipulation of the microbiota.

Trial registration number NCT03072641; Results.

  • COLORECTAL CANCER
  • PROBIOTICS
  • INTESTINAL MICROBIOLOGY
  • TUMOUR MARKERS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.